Cover Image
市場調查報告書

PharmaPoint:偏頭痛 - 全球醫藥品的預測與市場分析

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 305466
出版日期 內容資訊 英文 262 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:偏頭痛 - 全球醫藥品的預測與市場分析 PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年08月10日 內容資訊: 英文 262 Pages
簡介

偏頭痛治療藥市場由於學名藥而呈現飽合狀態,除了慢性偏頭痛治療藥Botox以外,已上市的其他品牌藥預測將在今後數年漸漸失去獨佔性。但既有產品的劑形改變、新類治療藥開始銷售,一般預測偏頭痛治療藥市場到2023年前將以CAGR3.6%的速度擴大到37億美金的規模。

本報告提供全球偏頭痛治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預後
  • 症狀
    • 前驅症狀階段
    • 徵兆階段
    • 頭痛階段
    • 以後症狀的階段

第4章 病因

  • 疾病的背景
  • 與風險要素並存疾病
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
  • 流行病學的預測
    • 偏頭痛的整體患病者
    • 各年齡的整體患病者
    • 性別的整體患病者
    • 已調整年齡的整體患病人數
    • 處於徵兆階段的偏頭痛和沒有的偏頭痛整體患病人數
  • 議論
  • 第5章 疾病的管理
  • 治療概要
    • 對嚴重的偏頭痛的治療
    • 預防
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介-領導品牌
    • Triptans
    • Imitrex (sumatriptan)
    • Zomig (zolmitriptan)
    • Amerge (naratriptan)
    • Maxalt (rizatriptan)
    • Axert (almotriptan)
    • Frova (frovatriptan)
    • Relpax (eletriptan)
    • Sumavel DosePro (sumatriptan)
    • Ergot Alkaloids
    • Beta Blockers
    • Anti-Epileptics
    • Antidepressants
    • Calcium Channel Antagonists
    • Botox (onabotulinum toxin A)

第7章 機會及未滿足需求

  • 概要
  • 未滿足需求的差距分析

第8章 開發平台評估

  • 概要
  • 臨床試驗的製圖(定位)
  • 階段及臨床各狀況:臨床試驗
  • 臨床開發中的潛力藥物

第9章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • GlaxoSmithKline
    • AstraZeneca
    • Merck
    • Vernalis
    • Almirall
    • Pfizer
    • Zogenix
    • NuPathe
    • Allergan
    • RedHill Biopharma
    • OptiNose
    • CoLucid Pharmaceuticals
    • SUDA
    • Revance Therapeutics
    • NeurAxon

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC153PIDR

Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

It is estimated that pharmaceutical sales in the migraine market were approximately US$3.3 Billion throughout the 7MM in 2016. The US contributed to over 70% of these sales, generating about US$2.3 billon, driven mainly by the sale of triptans (around US$1.5 Billion) and Botox (almost US$0.5 Billion). The only triptan to remain patented in the US in 2016 was Pfizer's Relpax, which consequently is the highest-selling brand within this class.

Global migraine sales are expected to grow to around US$8.5 Billion by 2026, at a Compound Annual Growth Rate (CAGR) of over 10%. The growth will be driven by the launch of several late-stage pipeline products, particularly the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) erenumab, galcanezumab, fremanezumab, and eptinezumab, developed by Amgen, Eli Lilly, Teva, and Alder respectively.

The major drivers of growth in the migraine market during the forecast period include -

  • The launch and uptake of Eli Lilly's lasmiditan and Allergan's ubrogepant, which have novel mechanisms that satisfy unmet needs in the acute treatment market.
  • The launch and uptake of Amgen's erenumab, Eli Lilly's galcanezumab, Teva's fremanezumab, Alder's eptinezumab, and Allergan's atogepant, which are the first migraine-specific prophylactic treatments.
  • The high annual cost of therapy for mAbs, which will mean they will generate high sales.
  • A rising prevalence of migraine in the 7MM throughout the forecast period, which will lead to an increase in the diagnosed and treated population and will drive sales.

The report "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026", provides Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -

  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Pfizer, Amgen, Eli Lilly, Teva, Alder Biopharmaceuticals, Merck & Co, Allergan, Zogenix, RedHill BioPharma, Desitin, Grupe JUSTE, Grunenthal.

Scope

  • Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 9

2 Migraine: Executive Summary 10

  • 2.1 Migraine Market Will Grow to $8.7 Billion by 2026 11
  • 2.2 Companies Often Target the Underserved Migraine Population 13
  • 2.3 Current Treatments Leave Major Unmet Needs in the Migraine Market 15
  • 2.4 Market Opportunities for New Entrants 16
  • 2.5 Late-Stage Pipeline Drugs Will Be a Key Driver in the Migraine Market 16
  • 2.6 What Do Physicians Think? 17

3 Introduction 22

  • 3.1 Catalyst 22
  • 3.2 Related Reports 22
  • 3.3 Upcoming Related Reports 22

4 Disease Overview 24

  • 4.1 Migraine Classification 24
  • 4.2 Etiology and Pathophysiology 25
    • 4.2.1 Etiology 25
    • 4.2.2 Pathophysiology 26
  • 4.3 Symptoms 27
    • 4.3.1 Premonitory Phase 27
    • 4.3.2 Aura Phase 27
    • 4.3.3 Headache Phase 28
    • 4.3.4 Resolution Phase 29
  • 4.4 Prognosis 29
  • 4.5 Quality of Life 30

5 Epidemiology 31

  • 5.1 Disease Background 31
  • 5.2 Risk Factors and Comorbidities 32
  • 5.3 Global and Historical Trends 34
    • 5.3.1 US 36
    • 5.3.2 5EU 36
    • 5.3.3 Japan 36
  • 5.4 Forecast Methodology 37
    • 5.4.1 Sources 38
    • 5.4.2 Forecast Assumptions and Methods 40
  • 5.5 Epidemiological Forecast for Migraine (2016-2026) 43
    • 5.5.1 Total Prevalent Cases of Migraine 43
    • 5.5.2 Age-Specific Total Prevalent Cases of Migraine 45
    • 5.5.3 Sex-Specific Total Prevalent Cases of Migraine 46
    • 5.5.4 Migraine Cases by Frequency of Occurrences 47
  • 5.6 Discussion 48
    • 5.6.1 Epidemiological Forecast Insight 48
    • 5.6.2 Limitations of Analysis 49
    • 5.6.3 Strengths of Analysis 49

6 Disease Management 50

  • 6.1 Diagnosis Overview 50
  • 6.2 Treatment Overview 51
    • 6.2.1 Treatment Guidelines and Leading Prescribed Drugs 51
    • 6.2.2 Clinical Practice 52
    • 6.2.3 Episodic Migraine 52
    • 6.2.4 Chronic Migraine 54
    • 6.2.5 Non-pharmacological Treatments 56
  • 6.3 US 56
  • 6.4 5EU 59
  • 6.5 Japan 62

7 Competitive Assessment 65

  • 7.1 Overview 65
    • 7.1.1 Maxalt (rizatriptan benzoate) 66
    • 7.1.2 Relpax (eletriptan hydrobromide) 70
    • 7.1.3 Treximet (sumatriptan succinate + sodium naproxen) 75
    • 7.1.4 Sumavel DosePro (sumatriptan succinate) 78
    • 7.1.5 Rizaport (rizatriptan benzoate) 81
    • 7.1.6 Onzetra Xsail (sumatriptan succinate) 85
    • 7.1.7 Other Triptans 90
    • 7.1.8 Botox (onabotulinum toxin A) 105
    • 7.1.9 Antidepressants 109
    • 7.1.10 Anti-epileptics 113
    • 7.1.11 Other Therapeutic Classes 118

8 Unmet Needs and Opportunity Assessment 120

  • 8.1 Overview 120
  • 8.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders 121
    • 8.2.1 Unmet Need 121
    • 8.2.2 Gap Analysis 122
    • 8.2.3 Opportunity 123
  • 8.3 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication 124
    • 8.3.1 Unmet Need 124
    • 8.3.2 Gap Analysis 125
    • 8.3.3 Opportunity 126
  • 8.4 Physician Education and Diagnosis 127
    • 8.4.1 Unmet Need 127
    • 8.4.2 Gap Analysis 128
    • 8.4.3 Opportunity 129
  • 8.5 Effective and Well-Tolerated Prophylactic Treatments 129
    • 8.5.1 Unmet Need 129
    • 8.5.2 Gap Analysis 131
    • 8.5.3 Opportunity 133

9 Pipeline Assessment 134

  • 9.1 Overview 134
  • 9.2 Clinical Trial Mapping 136
    • 9.2.1 Clinical Trials by Country and Class 136
  • 9.3 Promising Drugs in Clinical Development 137
    • 9.3.1 Lasmiditan (COL-144) 139
    • 9.3.2 Eptinezumab (ALD-403) 146
    • 9.3.3 Fremanezumab (TEV-48125) 153
    • 9.3.4 Galcanezumab (LY2951742) 160
    • 9.3.5 Erenumab (AMG-334) 166
    • 9.3.6 Ubrogepant (MK-1602) 172
    • 9.3.7 Atogepant (AGN241689) 178
    • 9.3.8 SUD-001 184
  • 9.4 Promising Drugs in Early-Stage Development 190
  • 9.5 Other Drugs in Development 190

10 Current and Future Players 191

  • 10.1 Overview 191
  • 10.2 Trends in Corporate Strategy 193
  • 10.3 GlaxoSmithKline 195
    • 10.3.1 Overview 195
    • 10.3.2 Portfolio Assessment 196

10.3.3 SWOT Analysis 197

  • 10.4 Merck & Co. 197
    • 10.4.1 Overview 197
    • 10.4.2 Portfolio Assessment 198

10.4.3 SWOT Analysis 199

  • 10.5 Pfizer 199
    • 10.5.1 Overview 199
    • 10.5.2 Portfolio Assessment 200

10.5.3 SWOT Analysis 201

  • 10.6 Allergan 201
    • 10.6.1 Overview 201
    • 10.6.2 Portfolio Assessment 202

10.6.3 SWOT Analysis 203

  • 10.7 Amgen 203
    • 10.7.1 Overview 203
    • 10.7.2 Portfolio Assessment 204

10.7.3 SWOT Analysis 205

  • 10.8 Eli Lilly 205
    • 10.8.1 Overview 205
    • 10.8.2 Portfolio Assessment 206

10.8.3 SWOT Analysis 207

  • 10.9 Alder Biopharmaceuticals 207
    • 10.9.1 Overview 207
    • 10.9.2 Portfolio Assessment 208

10.9.3 SWOT Analysis 208

  • 10.10 Teva 209
    • 10.10.1 Overview 209
    • 10.10.2 Portfolio Assessment 209

10.10.3 SWOT Analysis 210

11 Market Outlook 211

  • 11.1 Global Markets 211
    • 11.1.1 Forecast 211
    • 11.1.2 Drivers and Barriers - Global Issues 214
  • 11.2 US 214
    • 11.2.1 Forecast 214
    • 11.2.2 Key Events 217
    • 11.2.3 Drivers and Barriers 217
  • 11.3 5EU 218
    • 11.3.1 Forecast 218
    • 11.3.2 Key Events 220
    • 11.3.3 Drivers and Barriers 220
  • 11.4 Japan 221
    • 11.4.1 Forecast 221
    • 11.4.2 Key Events 223
    • 11.4.3 Drivers and Barriers 223

12 Appendix 224

  • 12.1 Bibliography 224
  • 12.2 Abbreviations 237
  • 12.3 Methodology 241
    • 12.3.1 Forecasting Methodology 241
    • 12.3.2 Diagnosed Migraine Patients 241
    • 12.3.3 Percent Drug-Treated Patients 242
    • 12.3.4 Drugs Included in Each Therapeutic Class 242
    • 12.3.5 Launch and Patent Expiry Dates 243
    • 12.3.6 General Pricing Assumptions 244
    • 12.3.7 Individual Drug Assumptions 245
    • 12.3.8 Generic Erosion 253
    • 12.3.9 Pricing of Pipeline Agents 253
  • 12.4 Primary Research - KOLs Interviewed for This Report 255
  • 12.5 Primary Research - Prescriber Survey 256
  • 12.6 About the Authors 257
    • 12.6.1 Analyst 257
    • 12.6.2 Therapy Area Director 257
    • 12.6.3 Epidemiologist 257
    • 12.6.4 Managing Epidemiologist 258
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology 258
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy 258
  • 12.7 About GlobalData 260
  • 12.8 Contact Us 260
  • 12.9 Disclaimer 261

List of Tables

1.1 List of Tables

  • Table 1: Migraine: Key Metrics in the 7MM 10
  • Table 2: Migraine Classification from the ICHD-3 24
  • Table 3: Diagnostic Criteria for Migraine with Aura 28
  • Table 4: Diagnostic Criteria for Migraine without Aura 29
  • Table 5: Risk Factors and Comorbidities for Migraine 33
  • Table 6: ICHD-3 Diagnostic Criteria for Migraine 37
  • Table 7: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016-2026 44
  • Table 8: Treatment Guidelines for Migraine 51
  • Table 9: Most Prescribed Drugs for Migraine by Class in the 7MM, 2016 52
  • Table 10: Country Profile - US 58
  • Table 11: Country Profile - 5EU 61
  • Table 12: Country Profile - Japan 64
  • Table 13: Product Profile - Maxalt 67
  • Table 14: Maxalt SWOT Analysis, 2017 69
  • Table 15: Product Profile - Relpax 72
  • Table 16: Relpax Efficacy Clinical Trial Results 73
  • Table 17: Percentage of Patients with Headache Response (Mild or No Headache) 2 Hours Following Treatment 73
  • Table 18: Relpax SWOT Analysis, 2017 74
  • Table 19: Product Profile - Treximet 76
  • Table 20: Treximet SWOT Analysis, 2017 77
  • Table 21: Product Profile - Sumavel DosePro 79
  • Table 22: Sumavel DosePro SWOT Analysis, 2017 81
  • Table 23: Product Profile - Rizaport 83
  • Table 24: Rizaport SWOT Analysis, 2017 85
  • Table 25: Product Profile - Onzetra Xsail 87
  • Table 26: Onzetra Xsail SWOT Analysis, 2017 89
  • Table 27: Product Profile - Other Triptans 91
  • Table 28: Triptan SWOT Analysis, 2017 104
  • Table 29: Product Profile - Botox 107
  • Table 30: Botox SWOT Analysis, 2017 109
  • Table 31: Product Profiles - Antidepressants 111
  • Table 32: Antidepressants SWOT Analysis, 2017 112
  • Table 33: Product Profiles - Anti-epileptics 115
  • Table 34: Anti-epileptics SWOT Analysis, 2017 117
  • Table 35: Product Profile - Other Therapeutic Classes 119
  • Table 36: Unmet Need and Opportunity in Episodic and Chronic Migraine, 2017 121
  • Table 37: Migraine Late-Stage Pipeline, 2017 138
  • Table 38: Comparison of Therapeutic Classes in Development for Migraine, 2016-2026 139
  • Table 39: Product Profile - Lasmiditan 142
  • Table 40: Lasmiditan SWOT Analysis, 2017 145
  • Table 41: Product Profile - Eptinezumab (ALD-403) 148
  • Table 42: Eptinezumab (ALD-403) SWOT Analysis, 2017 152
  • Table 43: Product Profile - Fremanezumab (TEV-48125) 155
  • Table 44: Fremanezumab (TEV-48125) SWOT Analysis, 2017 159
  • Table 45: Product Profile - Galcanezumab (LY2951742) 162
  • Table 46: Product Profile - Erenumab (AMG-334) 168
  • Table 47: Erenumab (AMG-334) SWOT Analysis, 2017 171
  • Table 48: Product Profile - Ubrogepant (MK-1602) 174
  • Table 49: Ubrogepant (MK-1602) SWOT Analysis, 2017 177
  • Table 50: Product Profile - Atogepant (AGN241689) 180
  • Table 51: Atogepant (AGN241689) SWOT Analysis, 2017 183
  • Table 52: Product Profile - SUD-001 186
  • Table 53: SUD-001 SWOT Analysis, 2017 189
  • Table 54: Drugs in Development for Migraine, 2016 190
  • Table 55: Key Companies in the Migraine Market in the 7MM, 2016 191
  • Table 56: GlaxoSmithKline Disease Portfolio Assessment, 2017 197
  • Table 57: GSK SWOT Analysis, 2017 197
  • Table 58: Merck's Disease Portfolio Assessment, 2017 199
  • Table 59: Merck SWOT Analysis, 2017 199
  • Table 60: Pfizer's Disease Portfolio Assessment, 2017 201
  • Table 61: Pfizer SWOT Analysis, 2017 201
  • Table 62: Allergan's Disease Portfolio Assessment, 2017 203
  • Table 63: Allergan SWOT Analysis, 2017 203
  • Table 64: Amgen's Disease Portfolio Assessment, 2017 204
  • Table 65: Amgen SWOT Analysis, 2017 205
  • Table 66: Eli Lilly's Disease Portfolio Assessment, 2017 206
  • Table 67: Eli Lilly SWOT Analysis, 2017 207
  • Table 68: Alder's Disease Portfolio Assessment, 2017 208
  • Table 69: Alder SWOT Analysis, 2017 208
  • Table 70: Teva's Disease Portfolio Assessment, 2017 210
  • Table 71: Teva SWOT Analysis, 2017 210
  • Table 72: Migraine Market - Global Drivers and Barriers, 2016-2026 214
  • Table 73: Key Events Impacting Sales for Migraine in the US, 2016-2026 217
  • Table 74: Migraine Market - Global Drivers and Barriers in the US, 2016-2026 217
  • Table 75: Key Events Impacting Sales for Migraine in the 5EU, 2016-2026 220
  • Table 76: Migraine Market - Global Drivers and Barriers in the 5EU, 2016-2026 220
  • Table 77: Key Events Impacting Sales for Migraine in Japan, 2016-2026 223
  • Table 78: Migraine Market - Global Drivers and Barriers in Japan, 2016-2026 223
  • Table 79: Key Historical and Projected Launch Dates for Migraine 243
  • Table 80: Key Historical and Projected Patent Expiry Dates for Migraine 243
  • Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 256

List of Figures

1.2 List of Figures

  • Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026 12
  • Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period 14
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents Expected to be Licensed for the Treatment of Migraine During the Forecast Period 17
  • Figure 4: Pathophysiology of a Migraine 26
  • Figure 5: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016 35
  • Figure 6: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence 39
  • Figure 7: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency 40
  • Figure 8: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016 45
  • Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016 46
  • Figure 10: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016 47
  • Figure 11: Overview of the Development Pipeline in Migraine. Darkest circle indicates Phase III of development, the lightest circle Phase 135
  • Figure 12: Migraine Clinical Trials by Class and Country 136
  • Figure 13: Migraine Clinical Trials for Drugs in the Late-Stage Pipeline 137
  • Figure 14: A Competitive Assessment of the Late-Stage Pipeline Agents in Development for the Treatment of Migraine for 2016-2026 138
  • Figure 15: Clinical and Commercial Positioning of Lasmiditan (COL-144) 144
  • Figure 16: Clinical and Commercial Positioning of Eptinezumab (ALD-403) 151
  • Figure 17: Clinical and Commercial Positioning of Fremanezumab (TEV-48125) 158
  • Figure 18: Clinical and Commercial Positioning of Galcanezumab (LY2951742) 165
  • Figure 19: Clinical and Commercial Positioning of Erenumab (AMG-334) 170
  • Figure 20: Clinical and Commercial Positioning of Ubrogepant (MK-1602) 176
  • Figure 21: Clinical and Commercial Positioning of Atogepant (AGN241689) 182
  • Figure 22: Clinical and Commercial Positioning of SUD-001 188
  • Figure 23: Global Sales of Branded Products for Migraine by Company in 2016 and 2026 192
  • Figure 24: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period 193
  • Figure 25: Global (7MM) Sales Forecast by Country for Migraine in 2016 and 2026 213
  • Figure 26: Sales Forecast by Class for Migraine in the US in 2016 and 2026 216
  • Figure 27: Sales Forecast by Class for Migraine in the 5EU in 2016 and 2026 219
  • Figure 28: Sales Forecast by Class for Migraine in Japan in 2016 and 2026 222
Back to Top